Johnson Matthey posts higher Q3 API profits; Pfizer patent spat continues
Johnson Matthey saw demand for ADHD APIs increase in the third quarter, while sales of its pain management ingredients and bulk opiates declined.
Johnson Matthey saw demand for ADHD APIs increase in the third quarter, while sales of its pain management ingredients and bulk opiates declined.
US Pharma firms are prepared for delays in the supply chain caused by Winter Storm Juno thanks to advanced planning and backup generators, says a logistics expert.
Guidance to remove red tape in the clinical trial process has been commended by the industry body ACRO.
The strengthening US Dollar will reduce CRO revenues, say analysts, but firms which have global strategic deals could benefit from reduced operational costs.